Aussies with CVD at higher risk from COVID-19

By VIVA! Communications | April 21, 2020

Tracking the incidence of COVID-19 globally, it is understood that people over the age of 60 with a pre-existing chronic condition, such as cardiovascular disease (CVD) or diabetes, are considered at greater risk to serious infection and complications.1 There has been a high prevalence of CVD in those dying from COVID-19 in Italy and China, two of the worst…

Read More

The role of strategic communications in helping to navigate unchartered COVID-19 waters

By VIVA! Communications | April 7, 2020

Our very own VIVA! Communications Principal and owner, Kirsten Bruce, Sydney was recently quoted in pharmaceutical industry publication, Pharma in Focus on how to engage with staff while working from home during the current COVID-19 pandemic. Today, Kirsten shares further insights on how companies should communicate both internally and externally in this challenging, unchartered landscape.…

Read More

The rise of telehealth

By VIVA! Communications | April 5, 2020

For a long time, access to healthcare has been an ongoing struggle for many rural and remote communities around Australia, with many facing long wait times, limited access to specialist services, and the need to travel long distances to major cities. Furthermore, office-workers and parents with young children often have difficulty finding time to attend…

Read More

Aussies & Kiwis with incurable blood cancer receive newly subsidised treatment option

By VIVA! Communications | April 1, 2020

Today, VIVA! partnered with Celgene, a Bristol-Myers Squibb company, Multiple Myeloma Australia and Multiple Myeloma New Zealand to announce a newly reimbursed treatment option for Australians and New Zealanders living with incurable blood cancer, multiple myeloma. REVLIMID® (lenalidomide) – the first and only maintenance treatment in ANZ specifically indicated and reimbursed for those with newly…

Read More